A 56-year-old Texas rancher with a prior diagnosis of acquired erythropoietic protoporphyria secondary to an underlying myelodysplastic disorder developed an uncommon tumor, blastic plasmacytoid dendritic cell neoplasm (BPDCN). During his initial disease, analysis revealed a TET2 mutation, which is the most common mutation associated with BPDCN. This article discusses this unusual hematopoietic neoplasm, the possible evolution from erythropoietic protoporphyria, and the underlying myelodysplastic process.
CASE REPORT
A 56-year-old Texas rancher was diagnosed with erythropoietic protoporphyria secondary to an underlying myelodysplastic disorder, refractory anemia with ring sideroblasts, in 2014 (1) . His chromosome analysis revealed no abnormalities, but a mutational analysis revealed a TET2 mutation. His skin disease was well controlled with the high-dose beta-carotene supplement Lumitene and sun avoidance. Th e patient's blood counts were monitored regularly and remained within normal parameters.
In January 2017, he presented to the emergency room with severe abdominal pain. He stated that he had also noted slowly enlarging lymph nodes in the prior 2 weeks. Physical exam revealed a diff use violaceous rash across his trunk and upper extremities with diff use adenopathy in his neck, axillae, and groin. Blood work revealed an elevated white blood cell count of 250 × 10 9 /L with 70% blasts, a hemoglobin of 8.5 g/dL, a hematocrit of 24.7%, and a platelet count of 134 × 10 9 /L. Flow cytometry revealed a population of cells positive for CD4, CD56, and CD123 consistent with a blastic plasmacytoid dendritic cell neoplasm (BP-DCN). Th e diagnosis was confi rmed by bone marrow aspirate and biopsy with appropriate immunostains (Figure 1) .
Th e patient's karyotype was diploid, and an acute myeloid leukemia fl uorescent in situ hybridization panel was normal. CKit was negative. A TET2 mutation was detected on sequencing. Th e patient was initiated on a Hyper CVAD regimen ( cyclophosphamide, vincristine, doxorubicin, and dexamethasone). He developed severe disseminated intravascular coagulation, respiratory distress, and renal insuffi ciency but slowly recovered without serious morbidity. Th e plans are to continue his chemotherapy regimen with an eventual allogeneic bone marrow transplant. dendritic cells (2) (3) (4) . Th is entity has been known under various names including agranular CD4 + natural killer (NK) cell leukemia, blastic NK-cell lymphoma, blastic NK leukemia, and agranular CD4 + , CD56 + hematodermic neoplasm. In the 2016 revision to the World Health Organization classifi cation of myeloid neoplasms and acute leukemia, this entity is classifi ed under the acute myeloid leukemias (5) . Th is is a clinically aggressive tumor derived from precursors of plasmacytoid dendritic cells, also known as professional type I interferon-producing cells or plasmacytoid monocytes (3) .
Th e clinical features of BPDCN consist of two main patterns (6). One is characterized by an indolent onset (70%-90% of cases) dominated by skin lesions followed by tumor dissemination. Th e other (10%-30% of cases) has features of acute leukemia and systemic involvement from the beginning. BPDCN is characterized by a diff use monomorphic blastic infi ltrate of cells that can resemble lymphoblasts or myeloblasts. Th e diagnosis is based on immunophenotyping and relies on expression of CD4 and CD56 along with antigens more specifi c for plasma dendritic cells, including CD123, TCL1, CD303, CD2AP, BCL11a, and SPIB. Currently there is no consensus as to the minimal phenotype necessary to establish the diagnosis, but it is proposed that a confi dent diagnosis may be established when four of the fi ve principal markers (CD4, CD56, CD123, TCL1, and CD303) are expressed (7, 8) .
T-cell and B-cell receptor genes are usually germline with clonal bystander T cells responsible for the rare cases of reported T-cell receptor gene rearrangements. Th ere are no specifi c karyotypic abnormalities, but complex aberrations may be present with six major recurrent targets, namely 5q (72%), 12p (64%), 13q (64%), 6q (50%), 15q (43%), and loss of chromosome 9 (28%) (9) . Next-generation sequencing shows that TET2 is the most common mutated gene (8) . Gene expression profi ling studies have shown a signature distinct from myeloid and lymphoid acute leukemia (10) . Th e presence of TET in the patient's original diagnosis along with the presence of TET2 in BPDCN raises the possibility that this current lesion may have arisen from his prior underlying myelodysplastic lesion. BPDCN appears to be commonly associated with myelodysplastic features (8) .
Despite the deceptively indolent clinical presentation with initial response in most cases to a variety of intensive chemotherapy regimens, the course is most always invariably aggressive, with median survival times from 10 to 16.4 months (7, 11) . Occasional reports have noted longer survival/remission times following allogeneic hematopoietic stem cell transplantation (12, 13) .
